Register for our free email digests:
Products
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Generics Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Teva Gets EU Backing For OTC Desloratadine
Teva subsidiary Ratiopharm has secured EMA backing for the EU-wide switch of allergy drug desloratadine.
Awards Offers Two Weeks Of Online Networking
From 20 October, a free online platform will allow registrants attending the digital Global Generics & Biosimilars Awards 2020 to participate in two weeks of dedicated networking activities ahead of the ceremony on 3 November.
Mylan Obtains CHMP Backing For Revlimid Generic In Two Indications
Mylan is taking aim at a lucrative oral solid formulation in Europe, with the European Medicines Agency’s Committee for Medicinal Products for Human Use recommending approval for the company’s generic version of Revlimid (lenalidomide) capsules.
Biosimilars Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Awards Offers Two Weeks Of Online Networking
From 20 October, a free online platform will allow registrants attending the digital Global Generics & Biosimilars Awards 2020 to participate in two weeks of dedicated networking activities ahead of the ceremony on 3 November.
Podcast: The UK's New Biosimilars Licensing Pathway
In this podcast discussion, Generics Bulletin editor David Wallace talks to Duncan Emerton, director of Custom Intelligence and Analytics for Informa Pharma Intelligence, about the UK's new licensing procedure for biosimilars.
Roche’s Biosimilar Losses Could Be Closer To CHF5bn
Roche entered the year with a projected hit to revenues from multi-source biosimilar competition to its three leading biologics. However, the number was increased at the half-year mark and could be set to ratchet up further, according to management.
Value-Added Medicines Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Awards Offers Two Weeks Of Online Networking
From 20 October, a free online platform will allow registrants attending the digital Global Generics & Biosimilars Awards 2020 to participate in two weeks of dedicated networking activities ahead of the ceremony on 3 November.
Industry Urges Medicare Rethink On 505(b)(2) Policy
Teva, Sun and the AAM are among those urging the CMS to rescind its proposal to reimburse Part B drugs approved under section 505(b)(2) as multiple source products. The proposal would target one relatively small but growing part of Medicare Rx spending and reflects CMS’ ongoing concern with fast rising costs in the program.
Intravenous Tramadol CRL Casts Shadow On Avenue’s Cipla Deal
Avenue’s two-stage deal with an arm of Cipla faces uncertainty following a US Complete Response Letter for its intravenous tramadol. The US firm says it is "very surprised" with the potential safety concern raised and plans to seek a meeting with the agency at the earliest to resolve the issue.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.